Sugi Predict

Sugi Predict / Compounds / SCHEMBL2933425

SCHEMBL2933425

SCHEMBL2933425

O=C(Nc1ccc(Cl)cc1)Nc1cnccc1CN1CC(=O)N(c2ccc(SC(F)(F)F)cc2)C1=O

nearest known ligand 0.38

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ IGF1R P08069 4/20 0.38
▸ TRPV1 Q8NER1 3/20 0.37
▸ MAPT P10636 2/20 0.36
▸ MEN1 O00255 2/20 0.36
▸ KMT2A Q03164 2/20 0.36
▸ RAB9A P51151 2/20 0.35
▸ NAMPT P43490 1/20 0.35
▸ NPC1 O15118 1/20 0.35
▸ SMN1; SMN2 Q16637 1/20 0.35
▸ KCNK3 O14649 1/20 0.34
▸ KCNK9 Q9NPC2 1/20 0.34
▸ KDM4E B2RXH2 2/20 0.34
▸ GRIK1 P39086 2/20 0.33
▸ ATR Q13535 1/20 0.33
▸ FLT1 P17948 1/20 0.33
▸ KDR P35968 1/20 0.33
▸ ALDH1A1 P00352 1/20 0.33
▸ HPGD P15428 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2934255 0.92 TRPV1 (0.41) IGF1RTRPV1RAB9ANPC1SMN1; SMN2
SCHEMBL2941266 0.89 KCNK2 (0.43) IGF1RTRPV1KMT2ANPC1SMN1; SMN2
SCHEMBL2941339 0.87 NPC1 (0.44) IGF1RRAB9ANAMPTNPC1KDR
SCHEMBL2939518 0.86 IGF1R (0.44) IGF1RATR
SCHEMBL2940347 0.86 IGF1R (0.39) IGF1RATR
SCHEMBL2938436 0.85 IGF1R (0.38) IGF1RTRPV1MEN1KMT2ARAB9A
SCHEMBL2939129 0.83 KCNK2 (0.39) IGF1RMEN1KMT2ARAB9ANPC1
SCHEMBL2939148 0.83 IGF1R (0.37) IGF1RMEN1KMT2ARAB9ANPC1
SCHEMBL2934254 0.83 IGF1R (0.41) IGF1RTRPV1MAPTNAMPT
SCHEMBL2936633 0.83 IGF1R (0.38) IGF1RALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7825115-B2 Cyclic urea compounds, preparation thereof and pharmaceutical use thereof as kinase inhibitors AVENTIS PHARMA S.A. (FR) 2010-11-02 — — US disclosed
EP-1599464-B1 NOVEL CYCLIC UREA DERIVATIVES, PREPARATION METHOD THEREOF AND PHARMACEUTICAL USE OF SAME AS KINASE INHIBITORS AVENTIS PHARMA SA (FR) 2010-09-22 — — EP disclosed
US-20080108654-A1 Cyclic Urea Compounds, Preparation Thereof and Pharmaceutical Use Thereof as Kinase Inhibitors AVENTIS PHARMA S.A. (FR) 2008-05-08 — — US disclosed
US-7354933-B2 Protein kinase inhibitors; antitumor agents; such as 5-methyl-1-quinol-4-ylmethyl-3-(4-trifluoromethanesulfonylphenyl)imidazolidine-2,4-dione trifluoroacetate AVENTIS PHARMA SA (FR) 2008-04-08 — — US disclosed
US-20040248884-A1 Novel cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors AVENTIS PHARMA S.A. (FR) 2004-12-09 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080108654-A1 Cyclic Urea Compounds, Preparation Thereof and Pharmaceutical Use Thereof as Kinase Inhibitors PRKG1, PRKACA, CMPK1 IGF1R 1595/4885TRPV1 4520/4885MAPT 1554/4885
US-20040248884-A1 Novel cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors PRKG1, PRKACA, PRKCA IGF1R 962/4885TRPV1 4322/4885MAPT 2136/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.